Re-listing - Enjie Co., Ltd. plans to acquire 100% of Zhongke Hualian, a high-tech enterprise specializing in the research and development of wet lithium-ion battery separator production equipment and other polymer material production equipment, leading to the resumption of its stock trading [1] - Guoao Technology's actual controller has changed to Xu Yinghui, resulting in the resumption of its stock trading [2] Capital Increase and Mergers - Tiens Wind Power plans to raise 1.95 billion yuan for the expansion of the Changfeng New Energy Equipment Manufacturing Base and other related projects [3] - Rese Intelligent plans to raise no more than 1.144 billion yuan for the development and industrialization of core components for intelligent equipment motion control and other projects [4] - Tiankang Biological intends to acquire 51% of Xinjiang Qiangdu Animal Husbandry Technology Co., Ltd. for 1.275 billion yuan in cash [5] Share Transfer and Buyback - Maide Medical plans to repurchase shares worth 20 million to 40 million yuan to reduce the company's registered capital [6] - Xice Testing's controlling shareholder Li Zexin intends to transfer 4.22 million shares at a price of 48.59 yuan per share, accounting for 5% [7] - Jintian Titanium Industry is inquiring about a share transfer price of 15.39 yuan per share for a total of 22.6625 million shares [8] External Investment and Daily Operations - Saiyi Information received approval for a major national science and technology project related to intelligent manufacturing systems and robotics [9] - Jiuan Medical's U.S. subsidiary received pre-market notification from the FDA for a home test kit for multiple viruses [10] - Jiazhe New Energy plans to invest in two wind power projects with a total installed capacity of 450 MW and an investment of approximately 2.366 billion yuan [11] - Junshi Biosciences received FDA approval for clinical trials of JS212 for the treatment of advanced malignant solid tumors [12] - Longsheng Technology plans to invest 350 million yuan in an innovative center for embodied intelligent robots [13] - Watson Bio's subsidiary received approval for clinical trials of a freeze-dried shingles virus mRNA vaccine [14] - Greeenmei plans to acquire 16.38% of Henan Circular Technology Industry Group for 400 million yuan [15] - Heng Rui Medicine's HRS9531 injection clinical trial has been approved, with no similar drugs approved globally for the MASH indication [16] - Guodian Power plans to invest 7.218 billion yuan in the expansion of the Guoneng Jianbi Phase 8 project [17] - Guorui Technology's subsidiary won a bid for the "GXLF Project Pump Source" project with a bid of 76 million yuan [18] - Xin Fengming plans to invest 280 million USD in a 360,000-ton functional fiber project in Egypt [19] - Chip Origin terminated the acquisition of 97% of Chip Lai Zhirong [20] - Moore Thread plans to use 7.5 billion yuan of idle raised funds for cash management [21]

Core Viewpoint - Enjie Co., Ltd. plans to acquire 100% of Qingdao Zhongke Hualian New Materials Co., Ltd. through a share issuance, aiming to enhance its production capabilities in the lithium battery separator market while addressing operational pressures and competition in the industry [1][3]. Group 1: Acquisition Details - Enjie intends to issue shares to 63 parties to purchase all shares of Zhongke Hualian and raise matching funds not exceeding 100% of the transaction price [1]. - The share issuance price is set at 34.38 yuan per share, representing a 37.9% discount from the last trading price before suspension [1]. - The specific transaction price is yet to be determined as the audit and evaluation of the target company are still ongoing [1]. Group 2: Zhongke Hualian's Role - Zhongke Hualian is one of the few manufacturers capable of providing complete wet lithium battery separator production lines and is a key supplier for Enjie [2]. - The company has established production bases with a total capacity expected to reach 30 billion square meters by the end of 2026, with plans for further expansion [2]. - Major clients include leading battery manufacturers such as CATL and BYD, with over 80% of its revenue coming from a few key customers, indicating a reliance risk [2]. Group 3: Impact on Enjie - The acquisition will allow Enjie to utilize Zhongke Hualian's production equipment and technology to produce high-performance separators, potentially lowering production costs [2][3]. - Enjie aims to quickly initiate equipment manufacturing and separator production line construction post-acquisition, enhancing its operational efficiency [3]. - The company is also looking to expand its overseas production capabilities to mitigate supply chain risks [3]. Group 4: Financial Performance and Risks - Enjie has faced significant financial challenges, reporting a 36.84% decline in net profit in 2023 and a projected net loss of 5.56 billion yuan in 2024, marking its first loss since going public [3]. - The company reported a revenue increase of 27.85% in the first three quarters of 2025, but net profit showed a loss of 86.32 million yuan, indicating a trend of increasing revenue without corresponding profit [4]. - As of September 30, 2025, Enjie had significant debt levels of 156 billion yuan against cash reserves of only 24.49 billion yuan, highlighting short-term repayment pressures [4].

"隔膜龙头"恩捷股份拟收购中科华联100%股份，股票复牌。 恩捷股份12月12日公告，拟通过发行股份的方式向郅立鹏、青岛众智达、陈继朝、杨波、袁军等共63名 交易对方购买其合计持有的青岛中科华联新材料股份有限公司（简称"中科华联"）100%的股份，并募 集配套资金。 截至目前，中科华联的审计和评估工作尚未完成，本次交易的具体交易价格尚未确定。恩捷股份股票将 于12月15日（星期一）开市起复牌。 中科华联成立于2011年，是专业研发、生产和销售湿法锂离子电池隔膜整套生产装备、其他薄膜等高分 子材料生产设备及隔膜制品的高新技术企业，主要客户为锂电池和锂电池隔膜厂商。 据悉，恩捷股份旨在通过本次收购实现产业链上游延伸，构建"设备+材料"的协同优势。公告指出，本 次交易完成后，恩捷股份将实现从隔膜装备到隔膜产品的产业链垂直整合，通过自身在锂电池隔膜领域 的技术优势与中科华联先进装备制造能力的深度融合，进一步释放产能潜力，在提产降本的同时实现产 业链协同与发展共赢。 2025年，恩捷股份相继推出高强度基膜、高浸润基膜以及阻燃隔膜等创新产品。同时，也已提前布局固 态电池领域，硫化物固态电解质十吨级中试产线也已全线贯通。 ...

本报记者李如是 12月12日晚间，云南恩捷新材料股份有限公司(以下简称"恩捷股份（002812）")发布公告称，拟通过发 行股份的方式向郅立鹏、青岛众智达、陈继朝、杨波、袁军等共63名交易对方购买其合计持有的青岛中 科华联新材料股份有限公司(以下简称"中科华联")100%的股份，并向不超过35名符合条件的特定对象发 行股份募集配套资金。公司股票将于12月15日开市起复牌。 公告显示，本次交易中，恩捷股份发行股份购买资产的发行股票价格为34.38元/股。截至上述预案签署 日，标的公司的审计和评估工作尚未完成，本次交易的具体交易价格尚未确定。 恩捷股份是全球领先的锂电池隔膜供应商，核心产品是锂电池隔离膜，主要应用于新能源汽车锂电池制 造领域、3C类产品及储能领域。公司不仅在全球产能布局、产品品质、成本效益以及技术研发等方面 具备显著竞争力，更是成功进入了全球绝大多数主流锂电池生产企业的供应链体系，主要客户包括宁德 时代（300750）、中创新航、国轩高科（002074）、亿纬锂能（300014）、比亚迪（002594）、孚能科 技、天津力神等国内主流锂电池企业以及松下、LGES等海外公司，深度绑定多家全球知名电池 ...

公告显示，标的公司是专业研发、生产和销售湿法锂离子电池隔膜整套生产装备、其他薄膜等高分子材 料生产设备及隔膜制品的高新技术企业，主要客户为锂电池和锂电池隔膜厂商。隔膜生产装备方面，标 的公司作为国内领先的锂电池隔膜生产装备制造商，自2013年第一条锂电池隔膜生产演示线调试成功以 来，自主研发隔膜整套生产装备已超十年，湿法锂电池隔膜生产线荣获国内首台(套)重大技术装备称 号。标的公司隔膜生产装备技术优势包括单线年产能高、产线核心零部件已基本实现国产化替代、自主 开发隔膜管理系统和可快速切换产品线等。 交易完成后，上市公司可直接使用标的公司的隔膜生产装备及相应的生产工艺技术，自产高性能隔膜产 品，降低上市公司生产及运营成本。同时，上市公司凭借在锂电隔膜领域的长期生产实践和产能优势， 亦可运用自身经验及工艺积累促进标的公司隔膜生产设备的改进优化及扩产。标的公司隔膜产品可以对 上市公现有隔膜产品矩阵起到补充，进一步完善先进产能的布局，提升规模效应;同时，如标的公司可 获得足够建设资金支持，标的公司隔膜产线产能将会更快提升、业绩释放更加迅速。此外，上市公司作 为全球出货量最大的锂离子电池隔膜供应商，市场份额已连续多年处 ...

Group 1 - The company plans to acquire 100% of Zhongke Hualian's shares through a share issuance to 63 counterparties, with the specific transaction price yet to be determined as the audit and evaluation work is still ongoing [1] - Zhongke Hualian's brand, Lanketu, holds approximately 4.5% of the domestic market share in the wet lithium battery separator market, ranking sixth in the industry as of 2024 [1] - The acquisition is expected to enhance the company's existing separator product matrix, improve advanced capacity layout, and accelerate capacity expansion and performance release if sufficient construction funds are secured [1] Group 2 - Zhongke Hualian is a leading domestic manufacturer of lithium battery separator production equipment, having developed a complete set of separator production equipment over more than ten years [2] - The technical advantages of Zhongke Hualian's separator production equipment include high annual production capacity per line, basic localization of core components, and the ability to quickly switch production lines [2] - Post-acquisition, the company will utilize Zhongke Hualian's production equipment and technology to produce high-performance separators, thereby reducing production and operational costs [2]

恩捷股份（002812）(002812.SZ)披露发行股份购买资产并募集配套资金预案，公司拟通过发行股份的 方式向郅立鹏、青岛众智达、陈继朝、杨波、袁军等共63名交易对方购买其合计持有的中科华联100% 的股份，并向不超过35名符合条件的特定对象发行股份募集配套资金。本次交易的具体交易价格尚未确 定。 据悉，发行股份购买资产发行价格确定为34.38元/股，发行股份募集配套资金发行价格将不低于定价基 准日前20个交易日上市公司股票交易均价的80%。 公告显示，标的公司是专业研发、生产和销售湿法锂离子电池隔膜整套生产装备、其他薄膜等高分子材 料生产设备及隔膜制品的高新技术企业，主要客户为锂电池和锂电池隔膜厂商。隔膜生产装备方面，标 的公司作为国内领先的锂电池隔膜生产装备制造商，自2013年第一条锂电池隔膜生产演示线调试成功以 来，自主研发隔膜整套生产装备已超十年，湿法锂电池隔膜生产线荣获国内首台(套)重大技术装备称 号。标的公司隔膜生产装备技术优势包括单线年产能高、产线核心零部件已基本实现国产化替代、自主 开发隔膜管理系统和可快速切换产品线等。 交易完成后，上市公司可直接使用标的公司的隔膜生产装备及相应的生产工艺 ...

| 倒计时8天 | | --- | | 2025（第十届）起点锂电行业年会暨锂电金鼎奖颁奖典礼 | | &起点研究十周年庆典 | | 2025起点用户侧储能及电池技术论坛 | | 活动主题： 新周期 新技术 新生态 | | 活动时间： 2025年12月18-19日 | | 活动地址： 深圳市维纳斯皇家酒店（深圳国际会展中心京基百纳店）三楼维纳斯厅（深圳市宝安区沙井 | | 镇沙井路118号） | | 主办单位： 起点锂电、起点储能、起点研究院SPIR | | 赞助及演讲单位： 惠州潼湖生态智慧区管理委员会/逸飞激光/小鲁锂电/派能科技/莫洛奇/融捷能源/远 | | 东电池/诺达智慧/奥鸿智能/中天和/超业精密/北测新能源/蓝京新能源/贤辰智享/东唐智能/达力智能/ | | 亿鑫丰/爱签/和明机械/金力股份/孚悦科技/乾纳智能装备/多氟多/科迈罗/三合一体/果曼钠电/新能安/ | 12 月 10 日，佛塑科技（ SZ:000973 ）公告， 发行股份及支付现金收购金力股份 100% 股份于 12 月 9 日深交所过会通过。 据佛塑科技此前发布的公告显示，本次交易对价合计为 50.8 亿元，其中支付现金的金额为 ...

请上市公司代表结合行业发展趋势、市场供求关系、产品竞争力和报告期内盈利指标波动情形，说 明标的公司是否存在业绩下滑风险，本次交易的业绩承诺方案是否谨慎合理。同时，请独立财务顾问代 表发表明确意见。 中国经济网北京12月10日讯 深交所并购重组审核委员会2025年第13次审议会议于昨日召开，会议 审议结果显示，佛山佛塑科技集团股份有限公司（佛塑科技，000973.SZ）发行股份购买资产符合重组 条件和信息披露要求。 重组委会议现场问询的主要问题 需进一步落实事项 无 公司12月2日披露的《重大资产重组报告书(上会稿)》显示，本次交易方案由发行股份及支付现金 购买资产和募集配套资金两部分组成。本次发行股份及支付现金购买资产与募集配套资金的实施互为前 提，共同构成本次交易不可分割的组成部分，其中任何一项未获得所需的批准或其他原因导致无法付诸 实施，则上述两项均不实施；本次购买资产及募集配套资金发行的股份将同步办理发行、登记及上市手 续。 上市公司拟通过发行股份及支付现金的方式购买袁海朝、华浩世纪等102名交易对方持有的金力股 份100%的股份。本次交易完成后上市公司将持有金力股份100%的股份。 根据中联评估以20 ...

为全力落实好一揽子货币政策措施，紧扣重庆市建设"六区一高地"目标任务，中国人民银行重庆市分行 安排1000亿元低成本资金，围绕科技创新、绿色金融、提振消费、稳定外贸以及民营小微五大领域，创 设"渝科融""渝绿融""渝消融""渝通融""渝民融"五个百亿级货币政策工具支持计划，并通过构建"政策宣 贯+科技赋能+融资对接+效果评估+协调调度"五位一体的全链条金融服务体系，为五大领域高质量发展 提供有力资金支持。 货币政策工具支持计划实施以来，重庆落地支持计划专用额度1478亿元，支持经营主体16万余户。其 中，科创、民营领域超300亿元、绿色领域超100亿元，货币政策工具的牵引带动作用充分显现。 强化部门协同联动 科技赋能融资对接"提速" 中国人民银行重庆市分行加强与行业主管部门协同联动，在需求摸排、融资对接、问诊把脉方面形成合 力，推动金融机构运用科技化手段优化线上信贷流程。该行通过"长江渝融通"大数据平台向辖内银行累 计推送重点领域企业8.1万余户，全面提升服务效率。 重庆友强高分子材料股份有限公司深耕高分子改性材料研发与制造领域近二十年。近期，该企业精准把 握市场需求趋势，急需资金用于新型材料配方的研发工作。 ...